UQORA MAXIMUM UTI PAIN RELIEF- phenazopyridine hydrochloride tablet

Uqora Maximum UTI Pain Relief by

Drug Labeling and Warnings

Uqora Maximum UTI Pain Relief by is a Otc medication manufactured, distributed, or labeled by Bonafide Health, LLC dba Uqora, Pharbest Pharmaceuticals, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

Active ingredient (in each tablet)

Phenazopyridine Hydrochloride 99.5 mg .

Purpose

Urinary Tract Analgesic

Use

Fast relief from urinary pain, burning, urgency and frequency associated with urinary tract infections. Treatment should not exceed 2 days; see Directions.

Warnings

Do not exceed recommended dosage

Do not use: if you have Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency unless approved by your physician.

Ask doctor before use if you have

■ kidney disease
■ allergies to foods, preservatives or dyes
■ had a hypersensitive reaction to phenazopyridine

When using this product

■ stomach upset may occur, taking this product with or after meals may reduce stomach upset
■ your urine will become reddish-orange in color. This is not harmful, but care should be taken to avoid staining clothing or other items.

----

■ Long-term administration of phenazopyridine hydrochloride has induced neoplasia in rats (large intestine) andmice (liver). Although no association between phenazopyridine hydrochloride and human neoplasia has beenreported, adequate epidemiological studies along these lines have not been conducted.

Stop use and ask doctor if

■ your symptoms last for more than 2 days
■ you suspect you are having an adverse reaction to the medication

If pregnant or breast feeding, ask a health professional before use.

Keep out of reach of children. In case of an overdose, get medical help or contact a Poison Control Center right away 1-800-222-1222.

Directions

Adults and children 12 years and over:
■ take 2 tablets 3 times daily with a full glass of water, with or after meals as needed

■ Do not use for more than 2 days (12 tablets) without consulting a doctor.

Children under 12 years:

■ consult a doctor

Other information

■ this product may stain contact lenses ■ this product can interfere with laboratorytests including urine, glucose (sugar), and ketones tests ■ store at room temperature 15°-30°C (59°-86°F) in adry place and protect from light ■ Tamper evident: tablets sealed in blisters. Do not use if blister foil or seal isopen or damaged

Inactive ingredients

corn starch, croscarmellose sodium, hypromellose, lactose, magnesium stearate,microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, pregelatinized starch, silicon dioxide, sodiumstarch glycolate, talc and triacetin

PRINCIPAL DISPLAY PANEL

MAX STRENGTH MOST POWERFUL DOSE WITHOUT RX

uqora

FOUNDED BY A UTI SUFFERER

UTI PAIN RELIEF

MAX STRENGTH

FAST TARGETED RELIEF FOR

Burning

Pain & discomfort at the source unlike general pain relievers

Urgency

2 Day Supply

12 tablets

99.5 mg Phenazopyridine Hydrochloride

Not intended to replace medical care

INGREDIENTS AND APPEARANCE

UQORA MAXIMUM UTI PAIN RELIEF 
phenazopyridine hydrochloride tablet

Product Information
Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC: 73712-114
Route of Administration	ORAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
PHENAZOPYRIDINE HYDROCHLORIDE (UNII: 0EWG668W17) (PHENAZOPYRIDINE - UNII:K2J09EMJ52)	PHENAZOPYRIDINE HYDROCHLORIDE	99.5 mg

Inactive Ingredients
Ingredient Name	Strength
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)
STARCH, CORN (UNII: O8232NY3SJ)
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)
TALC (UNII: 7SEV7J4R1U)
POVIDONE (UNII: FZ989GH94E)
HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
TRIACETIN (UNII: XHX3C3X673)
LACTOSE (UNII: J2B2A4N98G)
MAGNESIUM STEARATE (UNII: 70097M6I30)

Product Characteristics
Color	brown	Score	no score
Shape	OVAL	Size	9mm
Flavor		Imprint Code	p99
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 73712-114-24	1 in 1 CARTON	10/27/2025
1		24 in 1 BLISTER PACK; Type 0: Not a Combination Product
2	NDC: 73712-114-12	1 in 1 CARTON	10/27/2025
2		12 in 1 BLISTER PACK; Type 0: Not a Combination Product

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		10/27/2025

Labeler - Bonafide Health, LLC dba Uqora (118327455)

Establishment
Name	Address	ID/FEI	Business Operations
Pharbest Pharmaceuticals, Inc.		557054835	manufacture(73712-114)